Healthcare Industry News:  Arbor Pharmaceuticals 

Biopharmaceuticals Oncology Acquisitions

 News Release - December 17, 2012

Eisai Inc. Divests U.S. Rights for GLIADEL(R) Wafer (polifeprosan 20 with carmustine implant) to Arbor Pharmaceuticals

WOODCLIFF LAKE, N.J. and ATLANTA, Dec. 17, 2012 -- (Healthcare Sales & Marketing Network) -- Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announced that it has entered into a definitive asset purchase agreement to divest U.S. rights for GliadelĀ® Wafer (polifeprosan 20 with carmustine implant) to specialty pharmaceutical company Arbor Pharmaceuticals, Inc. As part of the transaction, which takes effect immediately, Eisai has transferred the New Drug Application (NDA) for Gliadel to Arbor, with Arbor assuming responsibilities for all regulatory obligations and further development associated with the product in the United States. Eisai will retain all rights to Gliadel outside of the United States.

In addition, the companies have entered into a long-term supply agreement under which Eisai shall serve as Arbor's exclusive supplier of Gliadel for the U.S. market. Under the agreement, Eisai will manufacture Gliadel at its facility in Baltimore, Maryland, and will sell finished product to Arbor.

"The transition of U.S. rights for Gliadel to Arbor will ensure that patients who may benefit from treatment with Gliadel will continue to have access to it, while also enabling Eisai to reallocate funding and resources to other areas of our business to support our long-term business objectives," said Lonnel Coats, President & CEO of Eisai Inc. "As a human health care company, Eisai's focus is always on the needs of patients and their families. As such, we are very pleased that Arbor will be taking the lead on commercializing Gliadel in the U.S. moving forward."

"We are excited about our acquisition of U.S. rights to Gliadel and look forward to providing this important product to patients in the United States," said Jason Wild, Chairman of the Board of Arbor Pharmaceuticals, Inc. "We believe Gliadel has significant room to grow by maximizing its current use in all appropriate patients and through additional clinical studies for expanded indications. We expect Gliadel to fit in well with the hospital franchise being built at Arbor, which includes our new drug application (NDA) filed for the approval of an orphan-designated product, nimodipine oral solution."

"As part of the transaction Arbor will assume control of the contract sales team promoting Gliadel in the U.S. with plans to increase the promotional and medical support behind the product. In addition to Gliadel, this team will promote nimodipine oral solution and other future hospital-based products once approved. Arbor will continue to support the Gliadel clinical studies underway and pursue additional clinical development opportunities," added Ed Schutter, President & CEO of Arbor.

About GLIADELĀ® Wafer (polifeprosan 20 with carmustine implant)

GLIADELĀ® Wafer is indicated in patients with newly diagnosed high-grade malignant glioma as an adjunct to surgery and radiation.

GLIADEL Wafer is also indicated in patients with recurrent glioblastoma multiforme as an adjunct to surgery.

Please see Full Prescribing Information.

Eisai Inc.

Eisai Inc. was established in 1995 and began marketing its first product in the United States in 1997. Since that time, Eisai Inc. has rapidly grown to become a fully integrated pharmaceutical business. Eisai's key areas of commercial focus are neurology and oncology. The company serves as the U.S. pharmaceutical operation of Eisai Co., Ltd., a research-based human health care (hhc) company that discovers, develops and markets products throughout the world.

Eisai has a global product creation organization that includes U.S.-based R&D facilities in Massachusetts, New Jersey, North Carolina and Pennsylvania, as well as manufacturing facilities in Maryland and North Carolina. The company's areas of R&D focus include neuroscience; oncology; vascular, inflammatory and immunological reaction; and antibody-based programs. For more information about Eisai, please visit www.eisai.com/US.

Eisai Co., Ltd.

Eisai Co., Ltd. is a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Through a global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide healthcare system.

About Arbor Pharmaceuticals, Inc.

Arbor Pharmaceuticals, headquartered in Atlanta, Georgia, is a specialty pharmaceutical company currently focused on the cardiovascular, pediatric and hospital markets. The company intends to become a leading specialty pharmaceutical company by actively licensing, developing and commercializing late-stage products for specialty focused conditions. Arbor currently markets multiple NDA and ANDA approved products with several more in development. For more information regarding Arbor Pharmaceuticals or any of its products, visit www.arborpharma.com or send email inquiries to info@arborpharma.com.


Source: Eisai

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.



FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.